Silence Therapeutics PLC Silence Therapeutics Appoints Craig Tooman as CFO (6838K)
January 06 2021 - 1:00AM
UK Regulatory
TIDMSLN
RNS Number : 6838K
Silence Therapeutics PLC
06 January 2021
Silence Therapeutics Appoints Craig Tooman as Chief Financial
Officer
6 January 2021
LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ("
Silence " or " the Company "), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced the appointment of
Craig Tooman as the Company's Chief Financial Officer (CFO) and
member of the Executive Leadership Team, effective immediately.
Mr. Tooman has a successful career in the biopharmaceutical
industry spanning more than 30 years, including 15 years of
experience as a public company CFO. Most recently, he was CFO and
COO at Vyome Therapeutics, and prior to this was CFO and then CEO
of Aratana Therapeutics where he successfully negotiated a merger
with Elanco. Before Aratana, Mr. Tooman was the CFO of Enzon
Pharmaceuticals until its acquisition by Sigma Tau, and prior to
that led the $1.1 billion M&A initiative and integration of
ILEX Oncology and Genzyme Corporation. He also held key positions
at Pharmacia and Upjohn. Mr. Tooman currently serves on the
Supervisory Board and Audit Committee of CureVac, which
accomplished a highly successful IPO on Nasdaq in August of
2020.
Mr. Tooman has a BA in Economics from Kalamazoo College and an
MBA from the University of Chicago.
Mark Rothera, President and CEO of Silence Therapeutics,
commented: "Craig brings a deep understanding of financial
strategy, U.S. capital markets and business development to Silence.
We are delighted to have him join Silence's Executive Leadership
Team. His appointment comes at a time of significant opportunity
and growth, highlighted by the advancement of our two wholly owned
product candidates into the clinic and three anticipated clinical
data readouts this year. His business and financial expertise will
be instrumental in helping us build our U.S. footprint and
positioning Silence as a leading global RNAi business."
Craig Tooman, incoming CFO of Silence Therapeutics, commented: "
Silence is a fast-growing company with ground-breaking technology
that stands out in the RNAi space. It is exciting to join at this
stage of the Company's journey, following a number of recent
successful partnerships and transformational deals. I look forward
to working with the team to continue the momentum."
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/ Angela Gray / Chris Welsh
silencetherapeutics@consilium-comms.com
U.S. IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary technology can be used to
engineer short interfering ribonucleic acids (siRNAs) that bind
specifically to and silence, through the RNAi pathway, almost any
gene in the human genome to which siRNA can be delivered. Silence's
wholly owned product candidates include SLN360 designed to address
the high and prevalent unmet medical need in reducing
cardiovascular risk in people born with high levels of
Lipoprotein(a) and SLN124 to address beta-thalassemia and
myelodysplastic syndrome. Silence is also developing SLN500, a C3
targeting program in partnership with Mallinckrodt Pharmaceuticals
to reduce the expression of the C3 protein for the treatment of
complement pathway-mediated diseases. Silence maintains ongoing
research and collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals and Takeda. For more information, please visit:
https://www.silence-therapeutics.com/
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements, including with respect to the Company's clinical and
commercial prospects. These forward-looking statements are not
historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders
and prospective security holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAPFSEFNFEFA
(END) Dow Jones Newswires
January 06, 2021 02:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024